International Journal of Urology | 2021

Impact of low‐dose tadalafil on adverse events after low‐dose‐rate brachytherapy for prostate cancer: A bi‐center randomized open‐label trial

 
 
 
 
 
 
 
 
 
 

Abstract

To study the efficacy of phosphodiesterase‐5 inhibitor tadalafil in attenuating adverse events after low‐dose‐rate brachytherapy for prostate cancer.

Volume 28
Pages None
DOI 10.1111/iju.14487
Language English
Journal International Journal of Urology

Full Text